Abbvie Inc. Common Stock (ABBV) 65.89 $ABBV
3 Biotech Stocks With a Higher Profit Margin Than Gilead Sciences, Inc.
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 03, 10:16AM CST
Source: StockMonkeys.com via Flickr. It's been a truly transformative year for Gilead Sciences and its shareholders. Even taking into consideration the latest swoon in Gilead's share price tied to the approval of AbbVie 's Viekira Pak and...
GILD: 94.91 (+0.65), ADMS: 17.49 (+0.12), ABBV: 65.89 (+0.45), ENTA: 50.45 (-0.40), PDLI: 7.68 (-0.03)
Novartis (NVS) Closes Sale of Animal Health Division to Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:10PM CST
Novartis (NVS) announced today that it has completed the divestment of its Animal Health Division to Eli Lilly and Company (LLY) for approximately $5.4 billion.
ABBV: 65.89 (+0.45), LLY: 70.06 (+1.07), GSK: 42.37 (-0.37), NVS: 92.25 (-0.41)
AbbVie Has Some Excellent Entries In Rheumatoid Arthritis
Clinically Sound Investor - at Seeking Alpha - Fri Jan 02, 2:55PM CST
ABBV: 65.89 (+0.45)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 42.37 (-0.37), XNPT: 8.83 (+0.06), OPXA: 0.77 (+0.05), SYN: 1.55 (+0.09), ABBV: 65.89 (+0.45), TEVA: 56.22 (-1.29), NVS: 92.25 (-0.41)
Dividend Investing At Work - December 2014
The Dividend Engineer - at Seeking Alpha - Fri Jan 02, 12:35AM CST
What's best than the first day of the year to review some notable dividend increases? Though December is typically not a very active month, three of my holdings increased their dividends. National Bank of Canada On December 5, National Bank of...
ABT: 44.90 (-0.12), GE: 25.06 (-0.21), SYF: 29.48 (-0.27), ABBV: 65.89 (+0.45)
Bull of the Day: Incyte (INCY) - Bull of the Day
Kevin Cook - ZACKS - Fri Jan 02, 12:00AM CST
Bull of the Day: Incyte (INCY) - Bull of the Day
PCYC: 124.46 (+2.20), GILD: 94.91 (+0.65), SGEN: 32.54 (+0.41), INCY: 73.76 (+0.65), ABBV: 65.89 (+0.45), AGIO: 109.76 (-2.28)
NeuroDerm Skyrockets on Parkinson's Disease Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 2:50PM CST
NeuroDerm (NDRM) announced encouraging top-line data from a phase IIa pharmacokinetic study on its levodopa/carbidopa candidates, ND0612H and ND0612L.
IPXL: 31.80 (+0.12), ABBV: 65.89 (+0.45), NDRM: 12.06 (-1.98), NVS: 92.25 (-0.41)
5 Biotech Stocks With Big News Due In January
at Investor's Business Daily - Wed Dec 31, 12:15PM CST
The biotech industry is set to hit the ground running in 2015, with January alone bringing a passel of potentially stock-moving events by some of the biggest players. The second full week of the month will bring the annual JPMorgan Healthcare...
BIIB: 342.01 (+2.56), ESRX: 84.65 (-0.02), VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48), CELG: 113.52 (+1.66)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
BIRT: 6.60 (unch), ACRX: 6.81 (+0.08), AWR: 38.15 (+0.49), ABBV: 65.89 (+0.45), ALGT: 149.86 (-0.47)
RBC provides commentary on Viekira Pak ramp up
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 7:12AM CST
GILD: 94.91 (+0.65), ABBV: 65.89 (+0.45)
Repros Gains on Positive Updates on the Status of Androxal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 4:20PM CST
Repros Therapeutics (RPRX) announced the submission of a complete response to the guidance regarding the expected NDA submission for Androxal.
MDCO: 26.63 (-1.04), RPRX: 9.72 (-0.25), ABBV: 65.89 (+0.45), AMAG: 42.60 (-0.02)
Roche's Ebola Test Gets FDA's Emergency Use Authorization - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 2:40PM CST
Roche (RHHBY) announced that the FDA has granted Emergency Use Authorization for the LightMix Ebola Zaire rRT-PCR Test.
AGN: 212.75 (+0.16), ABT: 44.90 (-0.12), ABBV: 65.89 (+0.45)
Coherus Biosciences: The Biosimilar Market Is Enormous And This Company Is Well Positioned
Regarded Solutions - at Seeking Alpha - Tue Dec 30, 2:08PM CST
AMGN: 159.89 (+0.60), ABBV: 65.89 (+0.45), CHRS: 15.82 (-0.50)
Gilead Long-Term Prognosis Is Promising
Stock Traders Daily - at Seeking Alpha - Tue Dec 30, 1:10PM CST
ESRX: 84.65 (-0.02), GILD: 94.91 (+0.65), MRK: 57.19 (+0.40), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48)
3 Biotech Stocks That Soared Past Gilead in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Dec 30, 9:41AM CST
Gilead (GILD) has been under pressure due to the pricing of its hepatitis C virus (HCV) treatments.
JNJ: 104.52 (-0.05), ESRX: 84.65 (-0.02), VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), ABBV: 65.89 (+0.45)
Start the New Year Off Right With the 3 Best Biotech Stocks
Motley Fool Staff - Motley Fool - Tue Dec 30, 6:43AM CST
Source: Flickr user dpotera . While many are popping champagne corks to welcome in the new year, we know that many fellow Fools (probably too many of us) will be wondering which companies could be the best bets for our portfolios in 2015. To help...
GILD: 94.91 (+0.65), ABBV: 65.89 (+0.45), CELG: 113.52 (+1.66)
3 Cheap Dividend Stocks You Can Buy Right Now
Sean Williams, The Motley Fool - Motley Fool - Tue Dec 30, 6:05AM CST
Source: TaxCredits.net via Flickr . Dividend stocks are the cornerstone of many well-run retirement portfolios -- that's a fact. The reason is that dividend stocks act as a beacon to investors, inviting them to take a deeper look into a...
VLO: 50.34 (+0.84), ESRX: 84.65 (-0.02), GILD: 94.91 (+0.65), ABBV: 65.89 (+0.45), ORAN: 16.88 (-0.04)
Billionaires Are Gobbling Up These Stocks Right Now
George Budwell, The Motley Fool - Motley Fool - Tue Dec 30, 5:55AM CST
The investing public tends to take a special interest in the stocks billionaire investors are buying or selling, often copying their behavior in hopes of beating the broader market. According to recent 13F filings submitted to the SEC, we have...
ABT: 44.90 (-0.12), ESRX: 84.65 (-0.02), GILD: 94.91 (+0.65), KITE: 60.61 (+2.94), PFE: 31.33 (+0.18), CLDN: 20.17 (+0.64), ABBV: 65.89 (+0.45)
Novartis' Cosentyx Approved in Japan for Psoriatic Arthritis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 3:20PM CST
Novartis (NVS) announced that the Japanese Ministry of Health, Labour and Welfare has approved Cosentyx (secukinumab) for the treatment of both psoriasis vulgaris and psoriatic arthritis (PsA) in adults who have failed to respond adequately to systemic therapies (except for biologics).
AGN: 212.75 (+0.16), ABT: 44.90 (-0.12), ABBV: 65.89 (+0.45), NVS: 92.25 (-0.41)
3 Biotech Stocks With a Higher Profit Margin Than Gilead Sciences, Inc.
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 03, 10:16AM CST
Source: StockMonkeys.com via Flickr. It's been a truly transformative year for Gilead Sciences and its shareholders. Even taking into consideration the latest swoon in Gilead's share price tied to the approval of AbbVie 's Viekira Pak and...
GILD: 94.91 (+0.65), ADMS: 17.49 (+0.12), ABBV: 65.89 (+0.45), ENTA: 50.45 (-0.40), PDLI: 7.68 (-0.03)
Novartis (NVS) Closes Sale of Animal Health Division to Eli Lilly - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 4:10PM CST
Novartis (NVS) announced today that it has completed the divestment of its Animal Health Division to Eli Lilly and Company (LLY) for approximately $5.4 billion.
ABBV: 65.89 (+0.45), LLY: 70.06 (+1.07), GSK: 42.37 (-0.37), NVS: 92.25 (-0.41)
AbbVie Has Some Excellent Entries In Rheumatoid Arthritis
Clinically Sound Investor - at Seeking Alpha - Fri Jan 02, 2:55PM CST
ABBV: 65.89 (+0.45)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 42.37 (-0.37), XNPT: 8.83 (+0.06), OPXA: 0.77 (+0.05), SYN: 1.55 (+0.09), ABBV: 65.89 (+0.45), TEVA: 56.22 (-1.29), NVS: 92.25 (-0.41)
Dividend Investing At Work - December 2014
The Dividend Engineer - at Seeking Alpha - Fri Jan 02, 12:35AM CST
What's best than the first day of the year to review some notable dividend increases? Though December is typically not a very active month, three of my holdings increased their dividends. National Bank of Canada On December 5, National Bank of...
ABT: 44.90 (-0.12), GE: 25.06 (-0.21), SYF: 29.48 (-0.27), ABBV: 65.89 (+0.45)
Bull of the Day: Incyte (INCY) - Bull of the Day
Kevin Cook - ZACKS - Fri Jan 02, 12:00AM CST
Bull of the Day: Incyte (INCY) - Bull of the Day
PCYC: 124.46 (+2.20), GILD: 94.91 (+0.65), SGEN: 32.54 (+0.41), INCY: 73.76 (+0.65), ABBV: 65.89 (+0.45), AGIO: 109.76 (-2.28)
NeuroDerm Skyrockets on Parkinson's Disease Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 2:50PM CST
NeuroDerm (NDRM) announced encouraging top-line data from a phase IIa pharmacokinetic study on its levodopa/carbidopa candidates, ND0612H and ND0612L.
IPXL: 31.80 (+0.12), ABBV: 65.89 (+0.45), NDRM: 12.06 (-1.98), NVS: 92.25 (-0.41)
5 Biotech Stocks With Big News Due In January
at Investor's Business Daily - Wed Dec 31, 12:15PM CST
The biotech industry is set to hit the ground running in 2015, with January alone bringing a passel of potentially stock-moving events by some of the biggest players. The second full week of the month will bring the annual JPMorgan Healthcare...
BIIB: 342.01 (+2.56), ESRX: 84.65 (-0.02), VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48), CELG: 113.52 (+1.66)
Zacks Rank #1 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Dec 31, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
BIRT: 6.60 (unch), ACRX: 6.81 (+0.08), AWR: 38.15 (+0.49), ABBV: 65.89 (+0.45), ALGT: 149.86 (-0.47)
RBC provides commentary on Viekira Pak ramp up
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 7:12AM CST
GILD: 94.91 (+0.65), ABBV: 65.89 (+0.45)
Repros Gains on Positive Updates on the Status of Androxal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 4:20PM CST
Repros Therapeutics (RPRX) announced the submission of a complete response to the guidance regarding the expected NDA submission for Androxal.
MDCO: 26.63 (-1.04), RPRX: 9.72 (-0.25), ABBV: 65.89 (+0.45), AMAG: 42.60 (-0.02)
Roche's Ebola Test Gets FDA's Emergency Use Authorization - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 2:40PM CST
Roche (RHHBY) announced that the FDA has granted Emergency Use Authorization for the LightMix Ebola Zaire rRT-PCR Test.
AGN: 212.75 (+0.16), ABT: 44.90 (-0.12), ABBV: 65.89 (+0.45)
Coherus Biosciences: The Biosimilar Market Is Enormous And This Company Is Well Positioned
Regarded Solutions - at Seeking Alpha - Tue Dec 30, 2:08PM CST
AMGN: 159.89 (+0.60), ABBV: 65.89 (+0.45), CHRS: 15.82 (-0.50)
Gilead Long-Term Prognosis Is Promising
Stock Traders Daily - at Seeking Alpha - Tue Dec 30, 1:10PM CST
ESRX: 84.65 (-0.02), GILD: 94.91 (+0.65), MRK: 57.19 (+0.40), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48)
3 Biotech Stocks That Soared Past Gilead in 2014 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Dec 30, 9:41AM CST
Gilead (GILD) has been under pressure due to the pricing of its hepatitis C virus (HCV) treatments.
JNJ: 104.52 (-0.05), ESRX: 84.65 (-0.02), VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65), ACHN: 13.33 (+1.08), ABBV: 65.89 (+0.45)
Start the New Year Off Right With the 3 Best Biotech Stocks
Motley Fool Staff - Motley Fool - Tue Dec 30, 6:43AM CST
Source: Flickr user dpotera . While many are popping champagne corks to welcome in the new year, we know that many fellow Fools (probably too many of us) will be wondering which companies could be the best bets for our portfolios in 2015. To help...
GILD: 94.91 (+0.65), ABBV: 65.89 (+0.45), CELG: 113.52 (+1.66)
3 Cheap Dividend Stocks You Can Buy Right Now
Sean Williams, The Motley Fool - Motley Fool - Tue Dec 30, 6:05AM CST
Source: TaxCredits.net via Flickr . Dividend stocks are the cornerstone of many well-run retirement portfolios -- that's a fact. The reason is that dividend stocks act as a beacon to investors, inviting them to take a deeper look into a...
VLO: 50.34 (+0.84), ESRX: 84.65 (-0.02), GILD: 94.91 (+0.65), ABBV: 65.89 (+0.45), ORAN: 16.88 (-0.04)
Billionaires Are Gobbling Up These Stocks Right Now
George Budwell, The Motley Fool - Motley Fool - Tue Dec 30, 5:55AM CST
The investing public tends to take a special interest in the stocks billionaire investors are buying or selling, often copying their behavior in hopes of beating the broader market. According to recent 13F filings submitted to the SEC, we have...
ABT: 44.90 (-0.12), ESRX: 84.65 (-0.02), GILD: 94.91 (+0.65), KITE: 60.61 (+2.94), PFE: 31.33 (+0.18), CLDN: 20.17 (+0.64), ABBV: 65.89 (+0.45)
Novartis' Cosentyx Approved in Japan for Psoriatic Arthritis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 3:20PM CST
Novartis (NVS) announced that the Japanese Ministry of Health, Labour and Welfare has approved Cosentyx (secukinumab) for the treatment of both psoriasis vulgaris and psoriatic arthritis (PsA) in adults who have failed to respond adequately to systemic therapies (except for biologics).
AGN: 212.75 (+0.16), ABT: 44.90 (-0.12), ABBV: 65.89 (+0.45), NVS: 92.25 (-0.41)
